Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$57.17 +0.5%	$58.32	$42.52 ▼ $62.89	$116.21B	0.26	9.35 million shs	27.57 million shs
LLY Eli Lilly and Company	$1,105.37 -1.9%	$955.92	$623.78 ▼ $1,149.10	$1.06T	0.48	3.09 million shs	4.60 million shs
MRK Merck & Co., Inc.	$118.49 -1.2%	$116.39	$75.40 ▼ $125.14	$296.11B	0.18	8.07 million shs	16.60 million shs
PFE Pfizer	$26.18 +0.2%	$26.77	$23.06 ▼ $28.75	$148.98B	0.35	33.36 million shs	48.26 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-1.21%	-4.45%	-2.27%	-8.52%	+21.18%
LLY Eli Lilly and Company	+3.81%	+8.14%	+28.89%	+7.26%	+56.79%
MRK Merck & Co., Inc.	-0.33%	+3.46%	+8.85%	-2.90%	+57.37%
PFE Pfizer	-0.32%	+0.89%	-1.10%	-5.26%	+12.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$57.17 +0.5%	$58.32	$42.52 ▼ $62.89	$116.21B	0.26	9.35 million shs	27.57 million shs
LLY Eli Lilly and Company	$1,105.37 -1.9%	$955.92	$623.78 ▼ $1,149.10	$1.06T	0.48	3.09 million shs	4.60 million shs
MRK Merck & Co., Inc.	$118.49 -1.2%	$116.39	$75.40 ▼ $125.14	$296.11B	0.18	8.07 million shs	16.60 million shs
PFE Pfizer	$26.18 +0.2%	$26.77	$23.06 ▼ $28.75	$148.98B	0.35	33.36 million shs	48.26 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-1.21%	-4.45%	-2.27%	-8.52%	+21.18%
LLY Eli Lilly and Company	+3.81%	+8.14%	+28.89%	+7.26%	+56.79%
MRK Merck & Co., Inc.	-0.33%	+3.46%	+8.85%	-2.90%	+57.37%
PFE Pfizer	-0.32%	+0.89%	-1.10%	-5.26%	+12.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.37	Hold	$61.31	7.24% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,227.00	11.00% Upside
MRK Merck & Co., Inc.	2.68	Moderate Buy	$128.18	8.17% Upside
PFE Pfizer	2.20	Hold	$28.82	10.08% Upside

Current Analyst Ratings Breakdown

Latest MRK, PFE, BMY, and LLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2026	BMY Bristol Myers Squibb	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/27/2026	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$27.00
5/26/2026	LLY Eli Lilly and Company	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,133.00 ➝ $1,251.00
5/26/2026	LLY Eli Lilly and Company	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1,119.00
5/22/2026	LLY Eli Lilly and Company	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,283.00
5/21/2026	LLY Eli Lilly and Company	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,350.00
5/21/2026	LLY Eli Lilly and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/21/2026	LLY Eli Lilly and Company	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$1,300.00 ➝ $1,330.00
5/19/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
5/15/2026	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
5/14/2026	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$26.00

(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.19B	2.42	$8.17 per share	7.00	$9.84 per share	5.81
LLY Eli Lilly and Company	$65.18B	15.97	$24.66 per share	44.83	$33.13 per share	33.36
MRK Merck & Co., Inc.	$65.01B	4.50	$11.29 per share	10.50	$18.60 per share	6.37
PFE Pfizer	$62.58B	2.38	$4.40 per share	5.95	$15.86 per share	1.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	$7.05B	$3.56	16.06	9.42	0.16	15.01%	64.87%	13.16%	7/30/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	39.27	24.94	1.23	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$3.55	33.38	12.12	2.70	13.59%	27.55%	10.73%	8/4/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	19.99	9.15	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)

Latest MRK, PFE, BMY, and LLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
4/30/2026	Q1 2026	BMY Bristol Myers Squibb	$1.42	$1.58	+$0.16	$1.31	$10.93 billion	$11.49 billion
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
4/30/2026	Q1 2026	MRK Merck & Co., Inc.	-$1.47	-$1.28	+$0.19	-$1.72	$15.85 billion	$16.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.52	4.41%	+1.61%	70.79%	17 Years
LLY Eli Lilly and Company	$6.92	0.63%	+15.18%	24.58%	11 Years
MRK Merck & Co., Inc.	$3.40	2.87%	+5.75%	95.77%	14 Years
PFE Pfizer	$1.72	6.57%	-13.20%	131.30%	16 Years

Latest MRK, PFE, BMY, and LLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/26/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.84%	6/15/2026	6/15/2026	7/8/2026
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026
3/2/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.23%	4/2/2026	4/2/2026	5/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.10	1.42	1.28
LLY Eli Lilly and Company	1.26	1.50	1.10
MRK Merck & Co., Inc.	1.02	1.30	1.06
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.05%
LLY Eli Lilly and Company	0.14%
MRK Merck & Co., Inc.	0.17%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.47 billion	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

MRK, PFE, BMY, and LLY Headlines

Recent News About These Companies

Pfizer's $10.5 Billion Oncology Bet Sends Innovent Shares Surging

2 hours ago | finance.yahoo.com

Arvinas to Present at Jefferies Global Healthcare Conference

2 hours ago | finance.yahoo.com

Insiders Aren’t Buying Pfizer Stock at $26 and That’s Actually a Good Thing

3 hours ago | finance.yahoo.com

Pfizer Expands Oncology Pipeline in $10.5B Innovent Deal

May 29 at 2:10 PM | finance.yahoo.com

Pfizer’s Real-World Lung Cancer Study on Dacomitinib: What Investors Should Know

May 29 at 12:50 PM | tipranks.com

Pfizer’s MET097 Obesity Trial Reaches Key Milestone: What Investors Should Watch Next

May 29 at 12:50 PM | tipranks.com

Pfizer’s VESPER-4 Obesity Trial Signals a Serious Push Into the GLP-1 Growth Market

May 29 at 12:50 PM | tipranks.com

Can AI crack pharma’s drug repurposing goldmine?

May 29 at 9:09 AM | pharmavoice.comP

Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal

May 29 at 9:09 AM | pharmaceutical-technology.comP

Pfizer and Innovent Biologics sign $10.5B cancer drug deal

May 29 at 9:09 AM | qz.comQ

Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 29 at 9:09 AM | finance.yahoo.com

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 29 at 8:00 AM | businesswire.com

Pfizer Inc. $PFE Stake Increased by National Pension Service

May 29 at 6:37 AM | marketbeat.com

Ilmarinen Mutual Pension Insurance Co Raises Stock Position in Pfizer Inc. $PFE

May 29 at 6:09 AM | marketbeat.com

Moors & Cabot Inc. Lowers Holdings in Pfizer Inc. $PFE

May 29 at 6:09 AM | marketbeat.com

Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies

May 29 at 4:31 AM | benzinga.com

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28 at 11:51 PM | finance.yahoo.com

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28 at 11:51 PM | finance.yahoo.com

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

May 28 at 11:10 PM | cnbc.com

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28 at 8:00 PM | businesswire.com

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

May 28 at 7:19 PM | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MRK, PFE, BMY, and LLY Company Descriptions

Bristol Myers Squibb NYSE:BMY

$57.17 +0.26 (+0.46%)

Closing price 03:59 PM Eastern

Extended Trading

$57.10 -0.08 (-0.13%)

As of 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Eli Lilly and Company NYSE:LLY

$1,105.37 -21.43 (-1.90%)

Closing price 03:59 PM Eastern

Extended Trading

$1,105.00 -0.37 (-0.03%)

As of 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$118.49 -1.40 (-1.17%)

Closing price 03:59 PM Eastern

Extended Trading

$118.84 +0.34 (+0.29%)

As of 07:53 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$26.18 +0.04 (+0.16%)

Closing price 03:59 PM Eastern

Extended Trading

$26.15 -0.03 (-0.13%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRK, PFE, BMY, and LLY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRK, PFE, BMY, and LLY Earnings

Compare Dividends

Latest MRK, PFE, BMY, and LLY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRK, PFE, BMY, and LLY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MRK, PFE, BMY, and LLY Company Descriptions

Bristol Myers Squibb NYSE:BMY

Eli Lilly and Company NYSE:LLY

Merck & Co., Inc. NYSE:MRK

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools